DAX25.127 ±0,0%Est505.904 -0,3%MSCI World4.343 -0,1%Top 10 Crypto12,10 -0,7%Nas23.480 -0,4%Bitcoin78.090 +0,1%Euro1,1650 -0,1%Öl62,45 -0,4%Gold4.468 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA Siemens 723610 Novo Nordisk A3EU6F RENK RENK73 Lufthansa 823212 Siemens Energy ENER6Y Allianz 840400 Amazon 906866 SAP 716460 Infineon 623100 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen in Grün -- Tilray reduziert Verluste und übertrifft Erwartungen -- TKMS führt Übernahmeverhandlungen mit GYNK -- Glencore, Rio Tinto im Fokus
Top News
Jetzt Neujahrsbonus sichern: 3 Geschenke für Neukunden bei unserem Broker finanzen.net ZERO Jetzt Neujahrsbonus sichern: 3 Geschenke für Neukunden bei unserem Broker finanzen.net ZERO
Wachstum mit Absicherung Wachstum mit Absicherung
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Anixa Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
2,88 EUR -0,02 EUR -0,69 %
STU
3,41 USD +0,13 USD +3,96 %
BTT
Anixa Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.92,64 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2N6ZF

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS03528H1095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolANIX

Anixa Biosciences Aktien News

DatumMeistgelesen
PR NewswireAnixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
PR NewswireAnixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
PR NewswireAnixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Wer­bungAnixa Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAnixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Comme...
PR NewswireAnixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
PR NewswireAnixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
PR NewswireAnixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
PR NewswireAnixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
PR NewswireAnixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
PR NewswireCleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
PR NewswireAnixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
PR NewswireAnixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
PR NewswireAnixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PR NewswireAnixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
PR NewswireAnixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
PR NewswireAnixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
PR NewswireAnixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
PR NewswireAnixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial
PR NewswireAnixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
PR NewswireAnixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
PR NewswireAnixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
PR NewswireAnixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
PR NewswireAnixa Biosciences to Host an Investor Webcast on June 26, 2025
PR NewswireAnixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
PR NewswireAnixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
PR NewswireAnixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR NewswireAnixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
PR NewswireAnixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
PR NewswireAnixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
PR NewswireAnixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
PR NewswireAnixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
PR NewswireAnixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
PR NewswireAnixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
PR NewswireAnixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
PR NewswireAnixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
PR NewswireAnixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
PR NewswireAnixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"
PR NewswireAnixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
PR NewswireAnixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
PR NewswireAnixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Anixa Biosciences News

Anixa Biosciences News: auf dieser Seite finden Sie alle Anixa Biosciences News und Nachrichten zur Anixa Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Anixa Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Anixa Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.